KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

KALV Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

KalVista Pharmaceuticals, Inc.NASDAQ: KALV

Stock-Based Compensation · Q4 FY2026 · quarter ended Dec 2025

Stock-based compensation of $0 in Q4 FY2026

Q4 FY2026 stock-based compensation was $0. Trailing-twelve-month stock-based compensation was $5.38M.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2026.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.34M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMDec 2025
$5.38M— YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2026
0 USD
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How KALV compares with its peers on the latest reported figures

  • KALV's LTM Dec 2025 stock-based compensation of $5.38M is the 9th largest of the 10 companies compared; the peer median is $12.84M.
  • Stock-based compensation amounts to 4.6% of revenue for KALV, versus a peer median of 20.8%.
KALV Competitors Peer median
Stock-Based Compensation for KALV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRTAProthena Corporation plcLTM Mar 2026$33.61M -24.5%+6.3%58.0%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$19.48M -28.2%+8.7%22.1%
GOSSGossamer Bio, Inc.LTM Mar 2026$14.45M -16.0%-37.2%26.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$13.21M -40.1%——
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$12.84M +21.4%+0.9%4.3%
ADCTADC Therapeutics S.A.LTM Mar 2026$12.63M +26.4%-48.5%16.0%
VSTMVerastem, Inc.LTM Mar 2026$9.66M +26.4%+15.9%19.5%
OMEROmeros CorporationLTM Mar 2026$5.74M +13.3%—58.0%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$5.38M ——4.6%
BCYCBicycle Therapeutics plcLTM Mar 2026$2.68M -107.0%+13.8%4.2%
Peer median (excluding KALV) $12.84M-16.0%+6.3%20.8%

Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Net Income(82.34M)(92.91M)(126.64M)(183.44M)(164.29M)
Depreciation & Amortization743K718K816K941K1.45M
Deferred Income Tax00000
Stock-Based Compensation09.92M21.92M12.29M0
Change in Working Capital(12.32M)7.41M15.17M15.04M954K
Accounts Receivables(5.2M)(2.32M)8.18M(3.62M)(7.4M)
Inventory0000(3.43M)
Accounts Payables1.69M1.11M4.32M(4.97M)4.19M
Other Working Capital(8.81M)8.62M2.67M23.63M7.59M
Other Non-Cash Items15.78M(407K)(485K)2.27M80.26M
Operating Cash Flow(78.13M)(75.26M)(89.23M)(152.91M)(81.62M)
Capital Expenditures(931K)(1.2M)(443K)(434K)(1.71M)
Acquisitions (Net)00000
Purchases of Investments(136.92M)(98.25M)(189.23M)(30.57M)(84.78M)
Sales of Investments195.71M140.86M104.96M122.52M105.36M
Other Investing Activities00(401K)00
Investing Cash Flow57.86M41.42M(84.72M)91.02M18.68M
Debt Repayment00098.04M160.72M
Common Stock Issued1.58M56.58M96.95M61.69M1.92M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities01.53M53.77M00
Financing Cash Flow1.58M58.12M150.71M159.73M162.64M
Effect of Forex Changes(1.17M)1.24M(1.21M)1.98M(1.98M)
Net Change in Cash(19.86M)25.51M(24.45M)99.83M97.73M
Free Cash Flow(79.07M)(76.46M)(89.67M)(153.34M)(83.33M)

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Intrinsic Alpha fair value

Locked

Current Price

$27.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.